Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06276491 · ClinicalTrials.gov registry record · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
A Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Xencor.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 282
- Enrollment target
- 16
- Study locations
NCT06276491: Recruiting Phase 1 study of Ovarian Cancer and Endometrial Cancer, sponsored by Xencor.
NCT06276491 is a Phase 1 study of Ovarian Cancer and Endometrial Cancer that is actively recruiting participants, run by Xencor. The registered enrollment target is 282 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (61% lower). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06276491, a Phase 1 study of Ovarian Cancer and Endometrial Cancer, is actively recruiting participants, sponsored by Xencor.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 282 participants
- Enrollment target
- 16
- Study locations
Study Summary
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
Conditions Studied
Interventions
- BIOLOGICAL XmAb541
Study Locations (16)
California
- City of Hope - Duarte
- Stanford - Palo Alto
- University of California - San Francisco
New York
- Icahn School of Medicine at Mount Sinai - New York
- Montefiore Einstein Comprehensive Cancer Center - The Bronx
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- University of Chicago Medical Center - Chicago
Indiana
- Indian University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- The John Theruer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2024-04-04 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
What NCT06276491 shows while recruiting
NCT06276491 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (61% lower).
The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which XmAb541 is the first listed.
NCT06276491 lists 16 locations in 13 states (California, New York, Florida).
Frequently Asked Questions
What is clinical trial NCT06276491 about?
NCT06276491 is a clinical study titled "Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors". The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.
What is the current status of trial NCT06276491?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 282 participants. The study started on 2024-04-04. Estimated completion is 2028-12.
What conditions does trial NCT06276491 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor.
What interventions are being tested in trial NCT06276491?
The interventions under investigation include: XmAb541 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06276491?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06276491 being conducted?
This trial has 16 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06276491's enrollment target sits among peer trials
282 75th of 322 higher than 248 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06369298 · 282 participants · Phase 2
Study of JK07 in Patients With Chronic Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI